Ascletis Pharma Inc
Healthcare · EUR · F
Price
€1.697
Cap
€1.72B
Earnings
—
30d Trend
-13.9%
66% annualised over 90 days
BRAIN47 SIGNAL
Raw weighted: 45×Macro 0.99 (−1%)=45
RISK
QUALITY
MOMENTUM
TECHNICAL
FUNDAMENTALS
Macro: neutral (×0.99) - Fear/Greed: 64 (Greed) - Data: 100%
BRAIN47 HORIZON ANALYSIS
3-6 month opportunity — emerging trend
BRAIN47'S ASSESSMENT
I rate Ascletis Pharma Inc at 45/100 — a MODERATE reading on the Brain47 Signal. The strongest factor is momentum at 76/100. I classify this as a speculative position with the strongest thesis on a medium-term horizon.
PAST PERFORMANCE
1 MONTH
-4.5%
3 MONTHS
+0.8%
12 MONTHS
+115.1%
Trailing returns — past performance, not a projection.
DETAILED ANALYSIS
3-6 month opportunity — emerging trend. Momentum (76) and Technical (57) are the primary strengths. I note that quality is the weakest area at 18/100 — this warrants monitoring. Historical volatility is elevated at 66%. I classify this as a speculative position — elevated volatility at 66% and smaller market cap define the opportunity.
Want full analysis on every stock?
Brain47 provides AI-powered research across 72,000+ instruments. Stocks, ETFs, REITs and more.
Join Brain47 — FreeGenerated by Brain47 AI. Educational research only. Not financial advice. Brain47 is not authorised by the FCA to provide investment advice.